Dec 21, 2021 8:30am EST Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Nov 02, 2021 4:01pm EDT Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 26, 2021 7:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update
Sep 28, 2021 4:00pm EDT Grifols begins commercializing TAVLESSE® in France, Italy and Spain to treat chronic immune thrombocytopenia
Sep 01, 2021 7:30am EDT Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
